New Delhi, August 19: Scientists in India have developed a groundbreaking cancer drug, RK-251, designed to selectively activate within cancer cells, potentially offering a less toxic alternative to conventional chemotherapy. This innovative approach aims to spare healthy tissues from the adverse effects commonly associated with cancer treatments.
Information was available with The Chenab Times indicating that traditional chemotherapy, while effective in combating cancer, often leads to significant side effects due to its indiscriminate action on both cancerous and healthy cells. The need for targeted therapies that remain dormant in healthy tissues and only become active at tumor sites has been a long-standing goal in cancer research.
Smart Drug Activation Mechanism
The research, spearheaded by Dr. Asis Bala from the Institute of Advanced Study in Science and Technology (IASST) and Dr. K.P. Bhabak from the Indian Institute of Technology-Guwahati, has culminated in the creation of RK-251. This novel drug is engineered to leverage the unique biochemical environment of cancer cells for its activation. Cancer cells are known to generate elevated levels of reactive oxygen species (ROS), harmful molecules essential for their proliferation. RK-251 is designed to respond to these high ROS concentrations. Upon entering a cancer cell, the drug is triggered by the abundance of ROS, leading to the release of NBDHEX, a potent anticancer compound.
Targeting Cancer Cell Survival Pathways
NBDHEX, once released within the cancer cell, works by inhibiting critical target proteins that many cancer cells rely on for their survival and to evade treatment. This targeted mechanism ensures that the drug’s therapeutic effects are concentrated where they are needed most, thereby reducing the potential for collateral damage to healthy cells.
Preclinical Study Results and Future Prospects
Preclinical investigations have demonstrated RK-251’s considerable efficacy against aggressive triple-negative breast cancer cells. Crucially, these studies also indicated a significantly reduced impact on healthy cells compared to conventional treatments. Further behavioral studies conducted on zebrafish embryos (Danio rerio) showed no apparent signs of toxicity. The drug exhibited the expected fluorescence in the presence of ROS, which is a positive indicator for its potential safety in future research phases. While these preliminary results are promising, extensive further studies are required before RK-251 can be considered for human clinical trials.
❤️ Support Independent Journalism
Your contribution keeps our reporting free, fearless, and accessible to everyone.
Or make a one-time donation
Secure via Razorpay • 12 monthly payments • Cancel anytime before next cycle
(We don't allow anyone to copy content. For Copyright or Use of Content related questions, visit here.)
The Chenab Times News Desk
